Table 1 Baseline characteristics of the 347 patients
Variable | Patients (%)/median (P25–P75)a | Variable | Patients (%)/median (P25–P75) | ||
|---|---|---|---|---|---|
Sex | Male | 290 (83.6) | Child class | A | 335 (96.5) |
Female | 57 (16.4) | B | 12 (3.5) | ||
Age (years) | ≥ 60 | 95 (27.4) | Performance status | 1 | 144 (41.3) |
< 60 | 252 (72.6) | 0 | 203 (58.2) | ||
HBsAg | Positive | 300 (86.5) | BCLC staging | Ad | 175 (50.4) |
Negative | 47 (13.5) | B | 17 (4.9) | ||
Liver cirrhosis | Yes | 222 (64) | C | 155 (44.7) | |
No | 125 (36) | AJCC staging | I | 166 (47.8) | |
Portal vein invasion | Yes | 21 (6.1) | II | 136 (39.2) | |
No | 326 (93.9) | IIIe | 45 (13) | ||
Ascites | Yes | 11 (3.2) | CNLC staging | I | 291 (83.9) |
No | 336 (96.8) | II | 33 (9.5) | ||
Ablation or TACE | Yes | 188 (54.2) | III | 23 (6.6) | |
No | 159 (45.8) | Neutrophil count | 3.6 (2.56–4.72) | ||
AFP (ng/ml) | > 400 | 132 (38) | Lymphocyte count | 1.45 (1.03–1.84) | |
≤ 400 | 215 (62) | Platelet count | 150 (109–205) | ||
Tumor capsule | Yes | 304 (87.6) | γ-GT | 60 (36–115) | |
No | 43 (12.4) | AST | 37 (27–53) | ||
Tumor number | ≥ 2 | 42 (12.1) | Total bilirubin | 15.2 (12–21.2) | |
1 | 305 (87.9) | Prothrombin time | 11.7 (11–12.4) | ||
Tumor size (cm) | > 5 | 168 (48.4) | Albumin | 44 (40.7–46.7) | |
≤ 5 | 179 (51.6) | Fibrinogen | 2.61 (2.13–3.27) | ||
MVIb | Yes | 172 (49.6) | NLR | 2.44 (1.71–3.37) | |
No | 175 (50.4) | PLR | 104.46(74.69–150.52) | ||
Cell differentiation | Poor | 35 (10.1) | GPR | 0.45 (0.22–0.88) | |
Moderate | 283 (81.6) | ALR | 26.97 (17.02–44.74) | ||
Well | 29 (8.4) | FAR | 0.06 (0.05–0.08) | ||
MKIc | Yes | 33 (9.5) | |||
No | 314 (90.5) |